Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma.
Dreyling, M Morschhauser, F Bouabdallah, K Cunningham, D Bron, D Assouline, S Verhoef, G Thieblemont, C Vitolo, U
Dreyling, M
Morschhauser, F
Bouabdallah, K
Cunningham, D
Bron, D
Assouline, S
Verhoef, G
Thieblemont, C
Vitolo, U
Citations
Altmetric:
Abstract
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma. 2016, 39: 310-310 Oncol Res Treat